REVOLUTION IN THE TREATMENT OF SEVERE INFECTIONS

CAL02

Severe bacterial and viral infections

Combioxin is a Swiss-based biotechnology company dedicated to the development of first-in-class life-saving drugs for severe infections.

The company is currently running two parallel programs on an innovative technology designed to fight severe bacterial and viral infections.

LATEST NEWS

Combioxin receives positive feedback from FDA on its pre-investigational new drug application (PIND) for use of CAL02 in COVID-19 patients at high risk of secondary bacterial infections
May 4, 2020

Pneumonia is the most common infection requiring hospitalization and admission to the intensive care unit (ICU), and is the third most common cause of death globally with 2.4 million deaths per year

There are >300 million cases per year

2’400 / day

CHILDREN < 5 YEARS DYING
OF PNEUMONIA

2.4 million

DEATHS CAUSED ANNUALLY
BY PNEUMONIA

Up to 50%

MORTALITY RATES OF
SEVERE PNEUMONIA

MEET THE TEAM

Samareh Azeredo da Silveira

Managing Director

Frédéric Lajaunias

Managing Director

Toni Perez

Chief Medical Director

Shelly Bustion

Head of Clinical Ops

Kristen Peterson

Head of CMC